Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐up-Reference-Cited by-同舟云学术

Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐up

Published:2020-01-28 Issue:3 Volume:104 Page:271-278
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Ahlstrand Erik¹^ORCID,Samuelsson Jan²,Lindgren Marie³,Pettersson Helna⁴,Liljeholm Maria⁵,Ravn‐Landtblom Anna⁶⁷,Scheding Stefan⁸⁹,Andréasson Björn⁴^ORCID

Affiliation:

1. Department of Medicine Faculty of Medicine and Health Örebro University Örebro Sweden

2. Department of Hematology University Hospital Linköping Linköping Sweden

3. Department of Medicine Kalmar County Hospital Sweden

4. Division of Hematology Specialist Medicine NU Hospital Group Uddevalla Sweden

5. Department of Hematology University Hospital of Northern Sweden Umeå Sweden

6. Department of Medicine Karolinska Institute Solna Sweden

7. Division of Hematology Department of Medicine Stockholm South Hospital Stockholm Sweden

8. Division of Molecular Hematology Department of Laboratory Medicine Lund Stem Cell Center Lund University Lund Sweden

9. Department of Hematology Skåne University Hospital Lund Sweden

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13373

Reference27 articles.

1. Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study

2. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

3. A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

4. Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera

5. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms;Clinical and Experimental Medicine;2024-05-22

2. Essenzielle Thrombozythämie und Polycythaemia vera;Die Onkologie;2023-02-28

3. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN);Leukemia;2023-02-24

4. Survival and risk of vascular complications in myelofibrosis—A population‐based study from the Swedish MPN group;European Journal of Haematology;2022-06-24

5. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia;Leukemia Research;2022-04